What is GenEdit?
GenEdit is a biotechnology firm dedicated to the discovery and development of innovative genetic medicines. At the core of its operations is the NanoGalaxy platform, a proprietary system utilizing non-viral, non-lipid polymer nanoparticles. This technology is designed to overcome traditional barriers in genetic medicine delivery, offering a safer and more effective alternative to existing methods. By leveraging this platform, GenEdit is not only advancing its internal therapeutic pipeline but also collaborating with strategic partners to deliver a diverse range of therapeutic payloads. The company occupies a critical niche in the biopharmaceutical sector, focusing on targeted in vivo delivery to address unmet medical needs.
How much funding has GenEdit raised?
GenEdit has raised a total of $118.5M across 4 funding rounds:
Angel/Seed
$8.5M
Series A
$26M
Other Financing Round
$24M
Series B
$60M
Angel/Seed (2018): $8.5M, investors not publicly disclosed
Series A (2021): $26M led by KB Investment, Lilly, DAYLI Partners, IMM Investment, Company K Partners, Korea Investment Partners, and KTB Network
Other Financing Round (2024): $24M supported by Genentech
Series B (2026): $60M featuring Kiwoom Investment, STIC Ventures, Sv Investment, Top Harvest Capital, Yuanta Investment, and DSC Investment
Key Investors in GenEdit
Kiwoom Investment
Kiwoom Investment is a prominent private equity and venture capital firm based in Seoul, specializing in high-growth sectors including healthcare, semiconductors, and eco-energy.
STIC Ventures
STIC Ventures is a leading Asian venture capital manager focused on fostering economic growth through strategic investments in promising, high-potential businesses.
Sv Investment
SV Investment is a Seoul-headquartered venture capital firm with a global footprint, providing critical financing and strategic guidance to companies in the life sciences and technology sectors.
What's next for GenEdit?
With the successful closure of its latest financing round, GenEdit is well-positioned to scale its research and development efforts. The strategic focus will likely shift toward advancing its lead candidates through clinical trials and expanding the utility of the NanoGalaxy platform. By maintaining a disciplined approach to capital allocation and leveraging the expertise of its diverse investor base, the company aims to solidify its market position as a leader in genetic medicine. Future milestones will likely include the expansion of its partnership network and the continued optimization of its nanoparticle delivery systems to support a broader array of therapeutic applications.
See full GenEdit company page
